- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT03284372
Safer Food Allergy Management for Adolescents
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
Among the 15 million people with food allergies in the United States, adolescents experience the highest risk of adverse events, including death from anaphylaxis. Visits to one pediatric emergency department for anaphylaxis doubled between 2001 and 2006, suggesting a rapidly escalating public health burden. Despite this critical concern, there are few evidence-based strategies to improve food allergy management in adolescents, who must sustain three core prevention strategies: diligent avoidance of allergenic foods, consistent carrying of potentially life-saving epinephrine auto-injectors, and prompt administration of epinephrine in the event of anaphylaxis.
The objective of this study is to develop and test interventions to encourage safer food allergy management among adolescents. The primary outcome is consistency of epinephrine-carrying, measured using cell phone photographs at randomly-timed check-ins. This study will be among the first to longitudinally track normative food allergy management practices and one of the first to test behavior change strategies.
In a cohort multiple randomized controlled trial (n=130), the study will include two experiments to test the effectiveness of text message reminders and incentives, using various incentive designs that have proven effective in prior behavioral economics interventions to encourage weight loss and smoking cessation. Aim 1. Test the impact of a text-message reminder system on consistency of epinephrine carrying. Aim 2. Test the impact of modest incentives on consistency of epinephrine carrying. Based on promising preliminary data, the central hypothesis is that, compared to controls, adolescents who receive text message reminders plus modest financial incentives will more consistently carry their epinephrine.
Tipo de estudo
Inscrição (Real)
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Estados Unidos, 19104
- Children's Hospital of Philadelphia
-
Philadelphia, Pennsylvania, Estados Unidos, 19104
- University of Pennsylvania
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Food allergy diagnosis by a physician and recorded in the medical chart
- Prior prescription of epinephrine auto-injector to treat anaphylaxis
- Access to a cell phone capable of sending and receiving text messages and photographs (our team will provide cell phones to participants willing to participate, but who do not own a cellphone)
- Fluent in English
- Between ages 15-19 at baseline
Exclusion Criteria:
- Unable to obtain permission (consent) of a parent to participate in the study
- Will not or cannot give assent
- Currently participating in another clinical trial with related aims
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Prevenção
- Alocação: Randomizado
- Modelo Intervencional: Atribuição fatorial
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
---|---|
Experimental: Intervention 1
Text Message Only
|
The intervention group (n=25, randomly selected from the base cohort) will receive informational and socially supportive text messages during a 10-week intervention.
Investigators will deploy the intervention using the Way to Health platform, which automates outgoing messages and feedback.
Many of the messages will be sent to all Intervention 1 participants, to assure consistency of the intervention.
A subset will be tailored to address participants' specific allergies.
At 10 unannounced check-ins, we will send text messages asking participants in the intervention and control groups if they are carrying their epinephrine.
|
Experimental: Intervention 2, Incentive
Text message + Incentive
|
Among base cohort members not exposed to the text message only intervention (#1), we will randomly select a new intervention group (n=50) to receive text message reminders plus Incentive 1.
At each of 10 unannounced check-ins, if unsuccessful in documenting epinephrine-carrying, participants will lose part of their incentive.
The remainder of the Cohort (control) will receive text reminders.
|
Sem intervenção: Cohort
For the cohort multiple randomized controlled trial (cmRCT), investigators will recruit 130 participants (the base cohort) ages 15-19.
The base cohort allows investigators to measure normative food allergy self-management practices, while also serving as a control for experiments in Interventions 1 and 2.
|
|
Sem intervenção: Control
The baseline cohort serves as the control group in this cmRCT.
Participants will not receive text message reminders (during Intervention 1) or incentives (during Intervention 2).
However, they will participate in all data collection points, including text message check-ins to assess epinephrine-carrying. Participants in the base cohort will receive usual care.
|
|
Sem intervenção: Adolescent Allergy Advisors
We will pilot the text messages to be used in Interventions 1 and 2 through interviews and cognitive testing among 20 Adolescent Allergy Advisors, who will critique message content, framing, and language.
These advisors will not be part of the cohort multiple randomized controlled trial.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Proportion of check-ins at which participant is carrying epinephrine auto-injector
Prazo: 10 randomly timed check-ins during the 10-week intervention period
|
Proportion of check-ins at which participant is carrying epinephrine auto-injector, measured using cell phone photographs
|
10 randomly timed check-ins during the 10-week intervention period
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Characterize adolescents' normative food allergy management practices
Prazo: Year-long cohort study
|
Characterize adolescents' normative food allergy management practices, measured comparing baseline and follow-up surveys that assess social challenges, out-of-home eating, allergen avoidance, and response to adverse events.
|
Year-long cohort study
|
Characterize adolescents' normative food allergy management practices
Prazo: Year-long cohort study
|
Characterize adolescents' normative food allergy management practices, measured using periodic text-message questions that assess social challenges, out-of-home eating, allergen avoidance, and response to adverse events.
|
Year-long cohort study
|
Develop a set of text message reminders to promote safer food allergy management among adolescents
Prazo: 2-year project period
|
Develop a set of text message reminders to promote safer food allergy management among adolescents by cognitively testing text message content
|
2-year project period
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Carolyn C Cannuscio, ScD, University of Pennsylvania
- Investigador principal: Jonathan Spergel, MD, Children's Hospital of Philadelphia
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 827073
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em Text Message Only
-
Boston UniversityNational Cancer Institute (NCI); Brown University; National Institutes of Health... e outros colaboradoresConcluído
-
Fundació d'investigació Sanitària de les Illes...Ativo, não recrutandoDiabetes Mellitus, Tipo 2Espanha
-
University of Southern CaliforniaConcluído
-
University of CalgaryUniversity of British Columbia; Alberta Health servicesRecrutamento
-
Fundació d'investigació Sanitària de les Illes...Inscrevendo-se por conviteIntervenção de saúde móvel para prevenir diabetes mellitus tipo 2 (estudo de fase II) (preDIABETEXT)Estado pré-diabéticoEspanha
-
Taipei Medical UniversityConcluído
-
Fundació d'investigació Sanitària de les Illes...ConcluídoDiabetes Mellitus, Tipo 2Espanha
-
Massachusetts General HospitalConcluídoDiabetes Mellitus, Tipo 2Estados Unidos
-
Northwell HealthNational Institute on Alcohol Abuse and Alcoholism (NIAAA)ConcluídoBeber álcool | Alcoolismo | Distúrbios Relacionados ao Álcool | Transtornos por Uso de Álcool | Abuso de ÁlcoolEstados Unidos